NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Eagle, I don't recall exactly when the number of 9 IDH mutants (about 2.7% of the trial) was established but if I remember correctly, it came out during a discussion of one of the first two presentations (NYAS or UK). I also recall that of the trials used for comparison, the Optune trial had a percentage of IDH mutants which was also low and roughly equivalent to our trial. The rest of the trials used for comparison did not present any IDH mutation data.

The IDH mutants are associated with methylated and pseudo-progressing GBM cases and the fact that few IDH mutants remained in the DCVax-L and Optune trials, strongly suggest that both trials made a serious effort to exclude pseudo-progressors and rapid progressors.

[https://pubmed.ncbi.nlm.nih.gov/27764705//quote]

It is good to know that IDH mutants are not a confounding factor in this trial.